Hepatitis C DNA vaccine - Pharmexa-Epimmune

Drug Profile

Hepatitis C DNA vaccine - Pharmexa-Epimmune

Latest Information Update: 27 Feb 2008

Price : $50

At a glance

  • Originator Pharmexa-Epimmune
  • Class Antivirals; DNA vaccines; Hepatitis C vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 18 Aug 2005 IDM S.A. has merged with Epimmune to form IDM Pharma
  • 30 Aug 2002 This vaccine is still in active development
  • 01 Mar 1999 Preclinical development for Hepatitis C in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top